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5-Hydroxytryptamine 2A (5-HT2A) receptors are es-
sential for the actions of serotonin (5-hydroxytrypt-
amine (5-HT)) on physiological processes as diverse as
vascular smooth muscle contraction, platelet aggrega-
tion, perception, and emotion. In this study, we investi-
gated the molecular mechanism(s) by which 5-HT acti-
vates 5-HT2A receptors using a combination of
approaches including site-directed mutagenesis, molec-
ular modeling, and pharmacological analysis using the
sensitive, cell-based functional assay R-SAT. Alanine-
scanning mutagenesis of residues close to the intracel-
lular end of H6 of the 5-HT2A receptor implicated gluta-
mate Glu-318(6.30) in receptor activation, as also
predicted by a newly constructed molecular model of
the 5-HT2A receptor, which was based on the x-ray
structure of bovine rhodopsin. Close examination of the
molecular model suggested that Glu-318(6.30) could
form a strong ionic interaction with Arg-173(3.50) of the
highly conserved “(D/E)RY motif” located at the inter-
face between the third transmembrane segment and the
second intracellular loop (i2). A direct prediction of this
hypothesis, that disrupting this ionic interaction by an
E318(6.30)R mutation would lead to a highly constitu-
tively active receptor with enhanced affinity for agonist,
was confirmed using R-SAT. Taken together, these re-
sults predict that the disruption of a strong ionic inter-
action between transmembrane helices 3 and 6 of
5-HT2A receptors is essential for agonist-induced recep-
tor activation and, as recently predicted by ourselves
(B. L. Roth and D. A. Shapiro (2001) Expert Opin. Ther.
Targets 5, 685–695) and others, that this may represent a
general mechanism of activation for many, but not all,
G-protein-coupled receptors.
5-Hydroxytryptamine 2A (5-HT2A)1 receptors are essential
for the actions of serotonin (5-hydroxytryptamine; 5-HT) on a
number of key physiological processes including platelet aggre-
gation, vascular and nonvascular smooth muscle contraction,
perception, and emotion (1). Additionally, 5-HT2A receptors
represent a major site of action of hallucinogens such as lyser-
gic acid diethylamide, which are agonists, and atypical anti-
psychotic drugs such as clozapine, which are antagonists (2).
5-HT2A receptors are unique in that both agonists and antag-
onists induce receptor internalization (3) that is dynamin-de-
pendent and arrestin-independent (4). Despite considerable
study (5–9), the molecular and atomic mechanisms by which
5-HT induces activation of the 5-HT2A receptor or of the other
15 cloned 5-HT receptors are currently unknown.
Prior studies have suggested several potential models of
agonist-induced activation of 5-HT receptors in particular and
other G-protein-coupled receptors (GPCRs) in general. Initial
site-directed mutagenesis studies of the 5-HT2A (10) and 1b-
adrenergic receptors (11, 12) as well as rhodopsin (13) impli-
cated a negatively charged residue in transmembrane helix 3
(H3), which could form a strong interaction with positively
charged/polar residues in H7 (“H3-H7 interaction model”). An-
other model (“H2-H7 proximity model”) (7) suggested that hy-
drogen bonding interactions between H2 and H7 were most
important for the activation of 5-HT2A receptors and gonado-
trophic hormone receptors (14). Predictions based on the
H2-H7 proximity model suggest that this could be a general
model for GPCR activation (14, 15). More recent studies have
predicted that agonist-induced activation of rhodopsin and 2-
adrenergic receptors (16, 17) and muscarinic m5 receptors (18,
19) occurs via agonist-induced rotations of H6 and H3 (“H3-H6
rotation model”). This model was quite recently modified based
on examination of the crystal structure of rhodopsin (20) and
extended to include disruption of a strong ionic interaction
between residues in H6 and H3 (“H6-H3 interaction model”)
(21, 41). Indeed, the H6-H3 interaction model has recently been
supported by mutagenesis and modeling studies of the 2-
adrenergic receptor (21).
In recent studies (6, 9), we demonstrated that the H3-H7
interaction model does not adequately describe agonist-induced
5-HT2A receptor activation. Instead, we have proposed (6, 22)
that agonists interact with H6 via aromatic residues and that
this interaction facilitates H6 motion and subsequent receptor
activation. We have also predicted (41) that agonist binding to
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residues in H6 leads to the disruption of a strong ionic inter-
action between H3 and H6. In the current study, we test this
“H3-H6 interaction model” via a combination of site-directed
mutagenesis and molecular modeling studies. Functional ex-
pression via R-SAT (receptor selection and amplification tech-
nology) was used to characterize the effects of receptor muta-
tions on basal, agonist-independent receptor activity. Taken
together, these results are consistent with a model of 5-HT2A
receptor activation in which agonists induce a disruption of a
strong ionic interaction between H3 and H6, which is facili-
tated by agonist-induced movements of H6. We also suggest,
based on an examination of aligned amino acids, that this is
likely to be a widely used, although not universal, mechanism
for agonist-mediated activation of G-protein coupled 5-HT
receptors.
MATERIALS AND METHODS
Receptor Numbering Schemes—Where appropriate, amino acid resi-
dues have been labeled both by standard amino terminus-based num-
bering and parenthetically by a numbering scheme introduced in 1995
by Ballesteros and Weinstein (23) in which relative amino acid positions
are highlighted. This scheme facilitates the efficient comparison of
residues within different GPCRs. With this method, every amino acid
identifier starts with the transmembrane helix number and is followed
by the position relative to a reference residue (arbitrarily assigned the
number 50) among the most conserved amino acids in that transmem-
brane helix. In the seven-transmembrane (TM) GPCRs, this general-
ized numbering scheme utilizes Asn-1.50, Asp-2.50, Arg-3.50, Trp-4.50,
Pro-5.50, Pro-6.50, and Pro-7.50 as seven reference positions, corre-
sponding in rat 5-HT2A receptors to Asn-92, Asp-120, Arg-173, Trp-200,
Pro-246, Pro-338, and Pro-377, respectively. Phe-340, for example, lies
two positions positive relative to Pro-338, yielding the identifier (6.52),
while one of the key residues studied in this manuscript, Arg-173(3.50)
is itself the most highly conserved residue in TM3.
Constructs and Antibodies—Mutant rat 5-HT2A receptors, expressed
in either pSVK3 (Amersham Biosciences, Inc.) or pCDNA3.1 (Invitro-
gen, Carlsbad, CA) were constructed by a PCR-based mutagenesis
technique as previously detailed for use in radioligand binding, phos-
phoinositide (PI) hydrolysis, and confocal microscopic studies (4, 6). A
5-HT2A-specific antibody was used for fluorescent confocal microscopic
studies as recently described (4). For R-SAT studies, mutations of
5-HT2A receptors were performed as previously detailed (24). All mu-
tations were confirmed by automated, fluorescent sequencing of the
entire insert (Cleveland Genomics, Cleveland, OH).
Transfection and Expression of Mutant 5-HT2A Receptors for Radio-
ligand Binding and PI Hydrolysis Experiments—Transfections of HEK-
293 cells were performed using Fugene-6 as previously described (4, 6).
For radioligand binding assays, cells were switched 24 h after transfec-
tion to Dulbecco’s modified Eagle’s medium containing 5% dialyzed fetal
calf serum, and 24 h later they were switched to serum-free Dulbecco’s
modified Eagle’s medium. Cells were then harvested 24 h later for
radioligand binding assays, which were performed as previously de-
scribed (4, 6). PI hydrolysis experiments were performed exactly as
previously detailed (4, 6). Receptor expression was verified concurrently
with binding experiments by immunohistochemistry using an antibody
specific for the 2A receptor.
R-SAT Assays—R-SAT (ACADIA Pharmaceuticals, San Diego, CA)
assays were performed with minor modifications from those previously
described (18, 19, 25). Briefly, NIH-3T3 cells were grown in 96-well
tissue culture plates to 70–80% confluence in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% calf serum and 1% penicillin/
streptomycin/Gln. Cells were transfected for 12–16 h with plasmid
DNAs using Superfect Reagent (Qiagen, Valencia, CA) per the manu-
facturer’s protocols. R-SATs were performed with 0.5–50 ng/well recep-
tor and 20 ng/well -galactosidase plasmid DNA. After overnight
transfection, medium was replaced with serum-free Dulbecco’s mod-
ified Eagle’s medium containing 2% cyto-sf3 (Kemp Biotechnologies,
Frederick, MD) and 1% penicillin/streptomycin/Gln and varying con-
centrations of drug. Cells were grown in a humidified atmosphere with
5% ambient CO2 for 4–6 days. Medium was removed from the plates,
and -galactosidase activity was measured by the addition of o-nitro-
phenyl -D-galactopyranoside (in phosphate-buffered saline with 5%
Nonidet P-40 detergent). The resulting colorimetric reaction was meas-
ured in a spectrophotometric plate reader (Titertek, Huntsville, AL) at
420 nM. All data were analyzed using the computer programs Excel Fit
and Prism (GraphPad, San Diego, CA). Significant differences were
determined by Student’s t test.
Molecular Modeling of Wild Type and Mutant 5-HT2A Receptors—
Energy minimizations and molecular dynamics simulations were per-
formed using the all atomic force field of the AMBER (Assisted Model
Building with Energy Refinement) 5.0 programs (26). Models of wild
type and mutant receptors were refined by using 500 steps of steepest
descent minimization followed by conjugate gradient energy minimiza-
tion until convergence with a 0.005 kcal mol1 Å1 root mean square
energy gradient difference between successive minimization steps. A
distance-dependent dielectric function (e  rij) and a 10-Å cut-off radius
for nonbonded interactions were used.
Molecular dynamics simulations in vacuo were performed for 1 ns at
300 K. The temperature was increased to 300 K during the first 30 ps
of each simulation. This was followed by an equilibrium period (30–500
ps) and a production run (500–1000 ps). For analysis purposes, struc-
tures were collected every 1 ps. The bond lengths involving hydrogens
were constrained by using the SHAKE algorithm, allowing an integra-
tion step of 0.001 ps. The secondary structure of helices was preserved
using distance restraints. These restraints were applied between the
backbone oxygen atom of residue i and the HN hydrogen atom of
residue i  4 in H1–H7 and the cytoplasmic helix, excluding prolines
and the part of H7 that attain a 3/10 helical conformation (restraints
between the backbone oxygen atom of residue i and the HN hydrogen
atom of residue i  3). The ICM (Internal Coordinate Mechanics) 2.8
Pro program (Molsoft L.L.C., La Jolla, CA) was used for all computer
graphics visualizations, for Biased Probability Monte Carlo simulations
(27), and for calculation of accessible surface area.
A model of the rat 5-HT2A receptor was constructed by using com-
puter graphics and molecular mechanics energy calculations. The
model included all parts of the amino acid sequence (residue ranges as
follows: Leu-71(1.29)–Thr-266(5.70) and Met-312(6.24)–Gln-398(7.71))
with the exception of the amino-terminal segment and most of the
carboxyl-terminal and third intracellular loop segments.
An initial model comprising the seven transmembrane helices, the
short loop between H1 and H2, a putative cytoplasmic helix after H7,
and part of the second extracellular loop was built by using the x-ray
structure of the inactive state conformation of bovine rhodopsin (20) as
a template. By using the WHATIF program (28), amino acid residues in
these parts of the bovine rhodopsin structure (chain A) were substituted
to their rat 5HT2A receptor counterparts. According to the mutation
data in Ref. 6, the rotational orientation of helix 5 was modified such
that the Phe-340(5.44) side chain pointed away from the binding site
and the Phe-243(5.47) and Phe-5.48 side chains pointed into the binding
site. The loop search feature of the SWISS-PDB VIEWER (version 3.7
beta 2) program (29) was used to identify candidate conformations for
each of the loops.
The extreme N- and C-terminal parts of the long third intracellular
loop were built as ideal -helical extensions of H5 and H6 using the
SWISS-PDB VIEWER. The C terminus of helices at Thr-266(5.70) and
Gln-398(7.71) was capped by NCH3, whereas the N terminus of helices
at Leu-71(1.29) and Met-312(5.24) was capped by COCH3. Model 1 was
obtained by energy minimization of this model. Two disulfide bridges,
Cys-148(3.25)-Cys-227 (second extracellular loop) and Cys-349–Cys-
353 (within the third extracellular loop), were introduced during the
energy minimization.
Models of the R173(3.50)E/E318(6.30)R, E318(6.30)R, and
V328(6.40)A mutants were constructed by substituting amino acids in
model 1 of the wild type receptor using ICM. The side chain dihedral
angles of residues at or near positions 3.50 and 6.30 in the R173(3.50)E/
E318(6.30)R, E318(6.30)R mutants were optimized by 100,000 steps in
biased probability Monte Carlo simulations (27) using the ECEPP/3
force field in ICM. The Monte Carlo stack conformation having the
lowest potential energy was further refined by energy minimization
using AMBER. The resultant energy-minimized models and model 1 of
the wild type receptor were used as the starting structure for molecular
dynamics simulations. An average conformation was calculated over
the last 500 ps of each molecular dynamics trajectory by using the
CARNAL program. This conformation was subsequently energy-mini-
mized using AMBER. The resulting models have been designated model
2 of the wild type and mutant receptors.
RESULTS
Alanine-scanning Mutagenesis Identifies Residues in H6
That Alter Agonist-induced 5-HT2A Receptor Activation—In
initial studies, we performed alanine-scanning mutagenesis of
12 residues (Ser-316(6.28)–Val-328(6.40)) at the i3/H6 inter-
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face. The residues at positions 6.33–6.37 are assumed to be
localized at a mixed hydrophobic-hydrophilic environment at
the lipid/water interface as proposed from spin labeling exper-
iments with rhodopsin (30). As shown in Table I, all of these
mutant receptors were expressed as functional receptors as
measured by [125I]DOI binding, although some variations in
receptor expression were measured. Immunochemical studies
also verified receptor expression (not shown). Table I also
shows that all mutants retained low micromolar or submicro-
molar affinities for 5-HT, although most mutants had slightly
increased (E318(6.30)A, C322(6.34)A, V324(6.36)A, L325-
(6.37)A, G326(6.38)A, and I327(6.39)A) or decreased (N317-
(6.29)A) affinities for 5-HT. Taken together, these results imply
that none of the residues is directly involved in ligand binding,
since very little change in [125I]DOI binding affinity was de-
tected and that the effects on agonist binding are likely to be
allosteric in nature.
We next examined the ability of these 12 H6 mutants to be
activated by 5-HT via measurements of 5-HT-mediated PI hy-
drolysis. As shown in Fig. 1 and Table II, the various mutant
5-HT receptors were differentially affected by alanine mu-
tagenesis. Four classes of mutations were discovered: 1) muta-
tions that enhanced the potency of 5-HT-stimulated PI hydrol-
ysis (E318(6.30)A, C322(6.34)A, V324(6.36)A, V328(6.40)A); 2)
mutations that diminished the potency of 5-HT-stimulated PI
hydrolysis (N317(6.29)A, Q319(6.31)A, K320(6.32)A); 3) mu-
tations that reduced the efficacy of 5-HT-stimulated PI hy-
drolysis (L325(6.37)A); and 4) mutations that had no effect on
5-HT-stimulated PI hydrolysis (S316(6.28)A, K323(6.35)A,
G326(6.38)A, I327(6.39)A). Visualization of the locations of
these residues in a 5-HT2A receptor model (model 1, Fig. 2a)
suggests that where mutation to alanine enhances agonist
potency, it probably does so via distinct mechanisms. Among
these, Glu-318(6.30) appeared to form an ionic interhelical
interaction with Arg-173(3.50), whereas the hydrophobic res-
idues had their side chains directed toward hydrophobic res-
idues in H5 (Cys-322(6.34)) or H7 (Val-324(6.36), Val-328-
(6.40)).
The side chains of all residues where mutation to alanine
decreased potency are predicted to be involved in intrahelical
hydrogen bonding interactions in model 1 (Fig. 2b, pre-MD
simulation). The side chain CO moiety of Gln-319(6.31) inter-
acted with the NH3
 moiety of Lys-320(6.32), whereas the NH2
moiety of Asn-317(6.29) interacted with one carboxylate oxygen
atom of Glu-318(6.30). In model 2 of the wild type receptor, the
Asn-317(6.29) side chain interacted with residues at the junc-
tion between H7 and the cytoplasmic helix (OH moiety of
Thr-386 (7.59) and main chain NH moiety of Lys-385 (7.58)),
whereas the Lys-320(6.32) side chain interacted with residues
in H5 (main chain CO moiety of Ala-265 (5.69)) and the side CO
moiety of Gln-319(6.31).
All residues where mutation to alanine did not affect 5-HT-
stimulated receptor activation (Ser-316(6.28), Lys-323(6.35),
Ile-327(6.39)) were localized on the membrane-facing surface of
H6 (Fig. 2b). The side chain of Leu-325(6.37), where mutation
to alanine decreased efficacy of 5-HT-stimulated PI hydrolysis,
was predicted to be localized in the cavity formed between the
transmembrane helices 2, 3, 6, and 7.
Molecular Modeling Predicts a Strong Ionic Interaction be-
tween H3 and H6 of the 5-HT2A Receptor—The localizations in
model 1 of the various residues of the 5-HT2A receptor that
TABLE I
Binding properties of WT 5-HT2A receptors and mutants
Saturation experiments using [125I]-DOI and competition binding
studies using [3H]ketanserin were performed on membrane prepara-
tions from HEK 293 cells transiently expressing WT or mutant recep-
tors. Values represent the means of three or more experiments  S.E.
All calculations were obtained using the software program Ligand for
DOS.
Mutant Kd DOI Bmax Ki 5-HT
nM fmol/mg M
WT 2A 0.47  0.09 173  14 0.90  0.17
S316A 0.46  0.05 412  21 1.2  0.06
N317A 0.43  0.07 357  21 2.1  0.59a
E318A 0.26  0.08 1137  136 0.29  0.05a
Q319A 0.67  0.10 491  34 1.1  0.49
K320A 3.17  0.89a 108  10 1.5  0.32
C322A 0.87  0.14 285  20 0.38  0.11a
K323A 0.74  0.18 180  16 0.54  0.17
V324A 0.89  0.17 306  24 0.25  0.10a
L325A 0.90  0.09 324  9.7 0.10  0.01a
G326A 0.52  0.08 272  16 0.29  0.07a
I327A 0.62  0.10 219  15 0.26  0.13a
V328A 0.28  0.02 728  36 0.62  0.37
a Significantly different from WT (p  0.05).
FIG. 1. Representative agonist-mediated PI hydrolysis Iso-
therms. Data represent means  S.E. of triplicate determinations for
the percentages of stimulation of PI hydrolysis in cells transfected with
wild type 5-HT2A or mutant receptors. Six log-serial dilutions of 5-HT
were incubated in a 24-well tissue culture plate in wells containing
transiently transfected HEK 293 cells, and the accumulation of [3H]-
inositol monophosphate was determined as described under “Materials
and Methods.” Data are expressed as percentages of native receptor
stimulation and are representative of three separate experiments.
TABLE II
WT and mutant receptor activation by 5-HT
PI hydrolysis activation isotherms for serotonin were obtained from
HEK 293 cells transiently transfected with WT or mutant receptors as
described. Kact values were calculated from EC50 using the software




WT 2A 18.1  1.2 101.2  4.1
S316A 36.8  9.0 92.0  5.1
N317A 91.5  20.6a 91.6  13.0
E318A 4.0  1.5a 88.5  14.1
Q319A 47.0  17.2a 71.3  6.7
K320A 137.4  17.5a 67.8  9.5
C322A 7.9  0.20a 87.0  3.6
K323A 10.4  2.4 70.2  16.6
V324A 6.7  1.2a 94.3  19.3
L325A 39.0  4.3 31.3  8.2a
G326A 7.7  1.7 90.1  11.4
I327A 22.6  5.1 77.1  6.8
V328A 0.54  0.04a 92.3  11.1
a Significantly different from WT (p  0.05).
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were targeted for alanine-scanning mutagenesis are shown in
Fig. 2, a and b. In this model, the carboxylate moiety of Glu-
318(6.30) was involved in 1) salt bridge/hydrogen bonding in-
teractions with the two NH2 moieties of Arg-173(3.50) and 2) a
hydrogen bonding interaction with the NH2 of Asn-317(6.29),
respectively (Fig. 2c). In model 2, the interaction between Arg-
173(3.50) and Glu-318(6.30) side chains was purely electro-
static and did not involve any direct hydrogen bonding inter-
actions (Fig. 2d). During the molecular dynamics simulation,
the side chains of Arg-173(3.50) and Glu-318(6.30) took part in
a network of hydrogen bonding interactions involving polar
side chains in H2, H6, and H7. The OH moiety of Thr-109(2.39)
interacted with the COO moiety of Glu-318(6.30) and the side
chain of Arg-173(3.50) as a hydrogen bond donor and acceptor,
respectively. In addition, the side chain of Arg-173(3.50) inter-
acted through hydrogen bonding interactions with the back-
bone CO group of Glu-318(6.30), whereas the COO moiety of
Glu-318(6.30) interacted through hydrogen bonding interac-
tions with the NH2 moiety of Asn-107(2.37), the OH moiety of
Thr-386(7.59), and the NH2 moiety of Asn-384(7.57).
Molecular Modeling of Wild Type and Mutant 5-HT2A Re-
ceptors Reveals Differences in Hydrogen Bonding Interactions—
Comparison of models 1 of wild type and the R173(3.50)E/
E318(6.30)R double mutant receptors revealed that the
arginine side chain adopted different conformations at posi-
tions 3.50 and 6.30 (Fig. 2c). In the wild type receptor, the
R173(3.50) side chain adopted a conformation that allows both
of its NH2 moieties to form hydrogen bonds to the carboxylate
moiety of Glu-318(6.30). In contrast, the Arg-318(6.30) side
chain adopted a conformation that allows its NH/NH2 face to
interact with E173(3.50) in the double mutant. This hydrogen
bonding/salt bridge interaction was also present in model 2 of
the R173(3.50)E/E318(6.30)R double mutant (Fig. 2e). How-
ever, additional interactions between the NH2/NH2 face of
R318 and the carboxylate moiety of D172(3.49) were also ob-
served in model 2.
In the energy-minimized average conformation of the
E318(6.30)R mutant, the side chain of Arg-173(3.50) had salt
bridge/hydrogen bonding interactions with Asp-172(3.49).
These interactions were not observed in the models of the wild
type receptor. The side chain of Arg-318(6.30) had hydrogen
bonding interactions with the backbone carbonyl moiety of
Ala-176(3.53) and the backbone CO and side chain OH moieties
of Ser-314(6.26) (Fig. 2f).
In the energy-minimized average conformation of
V328(6.40)A, the OE1 atom of the Glu-318(6.30) side chain had
hydrogen bonding interactions with Arg-173(3.50) and Thr-
109(2.39), whereas the OE2 atom of Glu-318(6.30) had hydro-
gen bonding interactions with Asn-317(6.29) and Lys-385(7.58)
(Fig. 2g). Comparison of the highly constitutively active mu-
tants V328(6.40)A and E318(6.30)R with the other constructs
(models 2) revealed important differences in hydrogen bonding
interactions in the polar pocket between helices 1, 2, and 7. The
Asp-120(2.50) side chain attained conformations that allowed it
to interact with the NH2 moiety of both Asn-92(1.50) and Asn-
376(3.49) in the models of V328(6.40)A and E318(6.30)R and
with the NH2 moiety of Asn-376(7.49) and the backbone moiety
of Thr-88(1.46) and Ser-373(7.46) in the model of the double
mutant (R173(3.50)E/E318(6.30)R).
Hydrophobic Type Interactions between Transmembrane Heli-
ces—It is possible that interhelical interactions between hydro-
phobic residues may also contribute to constraining the wild type
receptor to its inactive state conformation. The side chains of
three hydrophobic residues in H6 where alanine substitution
induces activation formed strong Van der Waals interactions
with residues in adjacent helices in model 1 (Cys-322(6.34): Arg-
173(3.50), Ile-177(3.54), Tyr-254(5.58), and Ile-258(5.62); Val-
324(6.36): Val-379(7.52), Phe-383(7.56), and Asn-384(7.57); Val-
328(6.40): Leu-113(2.43), Leu-166(3.43), Asn-376(7.49), and Val-
379(7.52)). Comparison of the different models obtained by
energy minimization of the average over the last 500 ps in mo-
lecular dynamics trajectories (models 2) revealed that the surface
exposure of the Val-324(6.36) side chain differed markedly (ratio
of accessible surface of Val-324(6.36) relative to standard exposed
surface for the residue type as follows: R173(3.50)E/E318(6.30)R:
0.06; WT: 0.23; V328(6.40)A: 0.27; E318(6.30)R: 0.49). In model 2
of the double mutant, the Val-324(6.36) side chain was buried
among Lys-323(6.35), Leu-325(6.37), Val-379(7.52), Tyr-
380(7.53), Asn-384(7.57), and Phe-383(7.56) close to the intracel-
lular end of H6 and H7.
Mutation Analysis of Residues Predicted to Form a Strong
Ionic Interaction—To test the prediction of the modeling stud-
ies that Arg-173 and Glu-318 formed a strong ionic interaction,
R173(3.50)E and E318(6.30)R as well as a double mutant con-
TABLE III
Binding and activation properties for WT2A and the reciprocal mutants
Binding studies using [3H]ketanserin and activation data were collected as described. Values represent the means of three or more experi-
ments  S.E.
Mutant Kd Ketanserin Bmax Ki 5-HT EC50 5-HT
nM fmol/mg nM nM
5-HT2A 0.53  0.14 1381  994 419.8  116.1 29.0  6.0
R173E 0.26  0.09 208  160 473.6  156.3 936  134a
E318R 0.54  0.11 737  442 49.4  11.2a 1.25  0.36a
R173E/E318R 0.36  0.08 618  396 464.3  168.3 358  121a
a Significantly different from WT (p  0.05).
FIG. 2. Models of the wild type rat 5-HT2A receptor (models 1 and 2), R173E/E318R double mutant (models 1 and 2), E318R (model
2), and V328A (model 2). Left column, models 1 obtained by using computer graphics and molecular mechanics energy calculations and the x-ray
structure of bovine rhodopsin as a template. a and b, the wild type 5-HT2A receptor viewed from the intracellular side in a view perpendicular to
the membrane surface. Residues where mutation to alanine increased potency of 5-HT-stimulated PI hydrolysis (red, oxygen; blue, nitrogen; white,
carbon; yellow, sulfur) and residues within a 3.0-Å radius of such residues in other helices (orange) are shown. b, residues where mutation to
alanine decreased (colored by atom type) or had no effect on (colored green) potency of 5-HT-stimulated PI hydrolysis and Glu-318(6.30) (colored
orange) are shown. c, a close up view of the intracellular parts of helices 3 and 6 in the wild type and R173(3.50)E/E318(6.30)R models 1 (the
junction between the helices and the intracellular domains is at the top in the figure) showing hydrogen bonding interactions as yellow lines. Right
column (d–g), models 2 obtained by energy minimization of an average over the last 500 ps in molecular dynamics trajectories showing the WT,
double mutant (E318(6.30)R/R173(3.50)E), E318(6.30)R, and V328(6.40)A, respectively. The side chains of residues at positions 3.50 and 6.30 and
residues having hydrogen bonding interactions (yellow lines) with these are displayed in ball and stick representations. Blue, Asp and Glu; red,
Lys and Arg. Residues having hydrogen bonding interactions with residues at positions 3.50 and 6.30 are color-coded by atom type (red, oxygen;
blue, nitrogen; white, carbon; grey, hydrogen). The mutated amino acid Ala-328 (6.48) and Val-375 (7.48) in H7 are displayed in CPK
representation.
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taining both mutations in a single plasmid were constructed.
As shown in Table III, receptor expression of the mutant con-
structs was variable but consistently greater than 200 fmol/mg.
Notably, the double mutant expressed functional receptor at
618 fmol/mg, intermediate between R173(3.50)E and the WT
receptor. The binding of [3H]ketanserin was not significantly
affected by any of the mutations. Agonist (5-HT) affinity, how-
ever, increased 10-fold in the E318(6.30)R mutant as predicted.
Receptor activation, as measured by PI hydrolysis, was most
severely inhibited by the R173(3.50)E mutation (Table III),
which showed a 32-fold decrease in agonist potency. Con-
versely, the E318(6.30)R mutation produced a 23-fold decrease
in potency. The double mutant E318(6.30)R/R173(3.50)E recov-
ered some but not all of the WT phenotype, yielding an EC50 for
5-HT 12-fold higher than the unmutated 2A receptor.
Basal PI hydrolysis was also examined for each of the mu-
tants used in this experiment. A titration of the cDNA used to
transfect HEK cells was performed, and the basal (unstimu-
lated) level of PI hydrolysis was measured (Fig. 3). Only the
E318(6.50)R mutant produced a detectable concentration-de-
pendent increase in basal PI hydrolysis (i.e. constitutive PI
hydrolysis activity). Basal, agonist-independent PI hydrolysis
increased with increasing DNA transfection concentration and
was detectable to below 0.5 g of DNA transfected per well of a
six-well culture plate. Untransfected HEK 293 cells displayed
less than 225 cpm (background) under the assay conditions
used (data not shown).
R-SAT Assays Confirm PI Activation Data and Accurately
Predict Constitutive Activity of Native and Mutant 5-HT2A
Receptors—R-SAT assays were then used to further define the
functional effects of the various 5-HT2A receptor mutants.
Seven selected receptor constructs representing the interface
between H3 and the i2 loop (R173(3.50)E), H6 (N317(6.29)A,
E318A(6.30)A, E318(6.30)R, K320(6.32)A, and V328(6.40)A)
and the double mutant (R173E/E318R) were chosen for R-SAT
analysis, and their respective potencies for the full agonist
serotonin, the full inverse agonist ritanserin, and their corre-
sponding degrees of constitutive signaling were determined. A
titration of the cDNAs used to transfect NIH3T3 cells as part of
the R-SAT assay was performed. As depicted in Fig. 4a, each
receptor mutant displayed a distinct and quantifiable degree of
basal signaling, which increased in a DNA concentration-de-
pendent manner. As depicted in Fig. 4 and Table IV, the WT
5-HT2A receptor displayed a moderate degree of basal signal-
ing (18  2%) in this assay. Mutagenesis of R173(3.50)E cre-
ated a significantly impaired receptor characterized by a com-
plete loss of basal signaling and a 60-fold decrease in potency
for serotonin (Fig. 4b and Table IV). The opposite phenotype
was observed for the E318(6.30)R mutant, which displayed
profoundly enhanced biological activity. This receptor was
nearly fully activated in the absence of 5-HT (89  11% basal
activity), precluding accurate determinations of functional po-
tency for serotonin. Interestingly, this mutant receptor dis-
played a 6.4-fold decrease in functional potency for the inverse
agonist ritanserin (Table IV). The double mutant R173(3.50)E/
E318(6.30)R displayed an intermediate phenotype, with a func-
tional potency for serotonin 7.6-fold greater than the
R173(6.30)E mutant yet 9.3-fold less than wild type and a
measurable but minimal degree of basal activity (3.8  2%). As
depicted in Fig. 4 and Table IV, the four remaining TM6 mu-
tants displayed a range of constitutive activity phenotypes. The
N317(6.29)A and K320(6.32)A mutants displayed a slight loss
of function with 5.0- and 2.2-fold decreased potency for sero-
tonin, respectively, coupled with a mild decrease in basal sig-
naling. The E318(6.30)A and V328(6.40)A mutants displayed
substantial and graded gain of function phenotypes character-
ized by increased potencies for serotonin (1.7- and 33-fold,
respectively) and decreased potencies for ritanserin (1.5- and
9.5-fold, respectively). These receptor mutants displayed sig-
nificant increases in basal signaling from the 18% seen with
the wild type receptor to 45 and 76%, respectively. In summary,
the rank order of constitutive activity of these 5HT2A receptors
as measured in this assay was R173(3.50)E  R173E/E318R
double mutant  N317(6.29)A  K320(6.32)A  WT 
E318(6.30)A  V328(6.40)A  E318(6.30)R.
DISCUSSION
The main findings of this study are that 1) a strong ionic
interaction (i.e. “salt bridge”) between Arg-173(3.50) in H3 and
Glu-318(6.30) in H6 of the 5-HT2A receptor stabilizes the in-
active state of the receptor, 2) disruption of this interaction
leads to constitutive activation of the 5-HT2A receptor, 3) hy-
drophobic interactions also appear to stabilize the inactive
state of the 5-HT2A receptor, and 4) functional expression of
directed H3 and H6 mutants that disrupt these normal inter-
actions can affect receptor expression as well as dramatically
affect potency for receptor agonists and inverse agonists.
In this study, we examined the effect of mutation of the
residues in the N-terminal part of H6 on receptor activation in
an attempt to determine the extent to which the residues in
this region play a role in receptor activation. It has been pre-
viously suggested that residues in the third intracellular loop of
the 5-HT2A receptor may be responsible for interactions with
G-proteins (Gq) and the transmission of subsequent effector
function (1), although direct tests of this hypothesis have not
been made previously.
The data from Table II suggest that a number of residues in
this region (Asn-317(6.29), Glu-318(6.30), Gln-319(6.31), Lys-
320(6.32), Cys-322(6.34), Val-324(6.36), Leu-325(6.37), and
Val-328(6.40)) all participate in the regulation of receptor ac-
tivity. Our current working model hypothesizes that the recep-
tor is stabilized in a “ground” or inactive state by interaction of
a number of charged and noncharged residues. Our model also
predicts that agonist binding is accompanied by a rotation of
TM6, leading to a subsequent rotational movement of H6 and
disruption of key stabilizing ionic interactions between resi-
dues of H6 and residues at the i2/H3 interface, although the
current study does not provide biochemical confirmation of this
prediction. Of the residues mutated in this study, those that
decreased potency after mutation to alanine are all predicted to
FIG. 3. Basal PI hydrolysis of WT and mutant 5-HT2A recep-
tors. Values represent mean cpm of tritiated inositol  S.E. collected
from three separate experiments each with triplicate determinations.
Data are plotted as a function of g of receptor DNA used to transfect
HEK 293 cells in six-well microtiter plates.
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be involved in intra- and interhelical hydrogen bonding inter-
actions. Such intra- and interhelical hydrogen bonding inter-
actions might play an important structural role in stabilizing
active state conformations. We cannot exclude the possibility
that the N317(6.29)A, Q319(6.31)A, and K320(6.32)A muta-
tions specifically disrupt hydrogen bonding interactions with
the Gq protein. Studies in progress
2 predict that portions of the
i3 loop may directly interact with Gq.
The (E/D)RY motif near the cytoplasmic end of TM3 is highly
conserved among the seven-transmembrane GPCRs.3 Within
this motif, Arg-3.50 is almost fully conserved in family 1
GPCRs (Arg in 98% of the sequences in the tGRAP10 family 1
alignment). There is now a growing body of evidence suggesting
that Arg-173(3.50) plays an important role in activation of
several GPCRs (15, 21, 31–33), although without a defined
mechanism. In support of our current hypothesis, and in direct
agreement with our findings, R135(3.50)W and R135(3.50)L
mutant rhodopsin receptors were found to be spectrally normal
(each bound 11-cis-retinal and was converted to the alternate
spectral form with max  380 nm upon illumination) but were
defective in the signal transduction pathway (32). Related find-
ings were reported for the 1B-adrenergic receptor (31), in
which D142(3.49)A caused significant constitutive activity. The
effect of direct alanine mutation of Arg-3.50 on the activity of
2 W. K. Kroeze and B. L. Roth, manuscript in preparation.
3 A detailed alignment of GPCRs can be found on the World Wide Web
at tGRAP.uit.no/fam1w.html.
FIG. 4. Constitutive activity of
5-HT2A receptor mutants revealed by
R-SAT. Reciprocal mutations of the H3
and H6 drastically affect 5HT2A receptor
basal signaling properties. a, constitutive
activity as a function of DNA concentra-
tion. NIH-3T3 cells were transiently
transfected with 0.5–50 ng/well receptor
DNA as part of the R-SAT assay. Consti-
tutive activity was defined as (basal re-
sponse — full inverse agonist response)/
(full agonist response — full inverse ago-
nist response) shown to reach maximal
levels at 25 ng/well receptor DNA. Data
are derived from 3–5 separate experi-
ments. S.E. bars have been omitted for
clarity but were all less than 15%. b, rep-
resentative concentration response
curves are shown for the full agonist se-
rotonin (filled squares) and the inverse
agonist ritanserin (filled diamonds) for
each of the receptor mutants assessed at
25 ng/well of plasmid DNA. Data are plot-
ted as the percentage response observed
in the R-SAT assay, defined as full ago-
nist response/full inverse agonist re-
sponse. The data are from nine-point con-
centration-response curves performed in
duplicate. Control (no drug treatment)
values are depicted on the left of each
graph.
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the 1B-adrenergic receptor was, however, undetermined. More
convincingly, direct mutation of the homologous residue in
gonadotropin-releasing hormone receptor to Gln, His, or Lys
severely inhibited agonist-induced inositol phosphate genera-
tion (15). Finally, in a most recent analysis of homologous
residues in the 2-adrenergic receptor, the authors propose
direct interaction of Arg-131(3.50) with Glu-268(6.30) and the
neighboring Asp-130(3.49) (21). Together, these findings sug-
gest an important role for Arg-173(3.50) in GPCR activation
that appears to be conserved across all receptor families.
E318(6.30)A showed considerable constitutive receptor activ-
ity by R-SAT (45% of the maximum stimulatable activity),
eclipsed only by V328(6.40)A (76%) and E318(6.30)R (89%).
Both of the tested E318(6.30) mutants had 1) enhanced affinity
for agonist binding, 2) enhanced potency for activation by 5-HT
(as measured by PI hydrolysis and R-SAT), and 3) increased
basal activity in both assay systems, all hallmarks of constitu-
tive activity. Interestingly, only mutations in the 5HT2A re-
ceptor that induced profound constitutive activity (70%,
E318R and V328A) displayed decreased functional potencies
for the full inverse agonist ritanserin. R-SAT confirmed the
basal signaling properties of the mutant receptors and proved
its utility for the measurement of inverse agonist responses in
those receptors for which routine measurements of constitutive
activity are unobtainable. The sensitivity of the R-SAT tech-
nology has already proven useful in identifying novel psycho-
therapeutic agents (e.g. antipsychotics) that differ more in their
inverse agonist than antagonist properties (34).
Interestingly, the E318(6.30)R mutation elicited greater con-
stitutive activity than E318(6.30)A, suggesting that a direct
polar repulsion between this residue and Arg-173(3.50) is at
least partially responsible for the constitutive phenotype. Re-
sults obtained with the E318(6.30)R mutant further suggest
that, within the guidelines of allowable motion of H6, addi-
tional rotation of this segment away from the ground state
conformation leads directly to increased receptor activity. The
double (reciprocal) mutant E318(6.30)R/R173(3.50)E had a
much reduced potency of 5-HT-stimulated PI hydrolysis and
minimal constitutive activity (3%) compared with the wild type
receptor. This could be explained by differences in the hydrogen
bonding interactions observed between the WT and the recip-
rocal mutant during molecular dynamics simulations (Fig. 2, d
and e) or after Monte Carlo simulations (Fig. 2c). During mo-
lecular dynamics simulations, stronger salt bridge/hydrogen
bonding interactions between H3 and H6 were observed in the
double mutant than in the wild type receptor. The
Arg-318(6.30) side chain of the double mutant interacted with
the Asp-172(3.49) and Glu-173(3.50) side chains (Fig. 2e),
whereas the Arg-173(3.50) side chain of the wild type receptor
interacted with Glu-318(6.30) (Fig. 2d). The R173(3.50)E mu-
tant had also the characteristics of an inactive state conforma-
tion. Interhelical interactions between E3.50 and other resi-
dues may lock this mutant in the inactive state.
According to the present mutagenesis and modeling data, it
is likely that interactions between hydrophobic residues in
helix 6 (Cys-322(6.34), Val-324(6.36), Val-328(6.40)) and heli-
ces 5 and 7 also contribute to the stabilization of inactive state
conformations. Amino acid substitutions at position 6.34 in rat
5-HT2A (35), rat 5-HT2C (36), and other family A receptors
(e.g. Refs. 37–39) have been shown to lead to constitutive ac-
tivity. Site-directed mutagenesis experiments with the Gq-cou-
pled AT1A angiotensin receptor have identified I245(6.40)L as
one of 16 single point substitutions that induce constitutive
activity (40). Finally, random saturation mutagenesis of TM6
in the muscarinic m5 receptor revealed a periodicity of mutants
that induce constitutive receptor signaling, leading the authors
to conclude that TM6 is involved in stabilizing the off state of
the receptor and that rotational changes in this portion of the
molecule were critical to receptor activation (18, 19, 25). Our
systematic mutagenesis and modeling studies confirm that
minor changes in the side chain volumes at the interfaces
between helices 6 and 7 and between helices 6 and 5 promote
constitutive receptor activation.
The molecular dynamics simulations of wild type and mu-
tant receptors also suggested that the transition from inactive
to active state conformations may involve a slight increase in
distance between the intracellular halves of H6 and H7. Inter-
estingly, the side chain of the highly conserved Asp-120(2.50)
changed conformation in the simulations of the constitutively
active mutants (V328(6.40)A and E318(6.30)R), leading to re-
arrangement in the hydrogen bonding interactions at the polar
pocket between helices 1, 2, and 7. This observation supports
previously incompletely explained findings from site-directed
mutagenesis studies, which suggested that both the Asp-120
and Asn-376 side chains are essential for 5-HT2A receptor
activation (7).
In conclusion, these studies imply that the ground (inactive)
state of the 5-HT2A receptor is stabilized by both ionic and
novel hydrophobic interactions involving residues in the intra-
cellular half of H6. A strong ionic interaction between Glu-
318(6.30) and Arg-173(3.50) was confirmed to be a major factor
in stabilizing the ground state of the 5-HT2A receptor. Finally,
R-SAT technology was used to precisely quantify the constitu-
tive activity of native and mutant GPCRs, providing insight
into the structural requirements for receptor activation.
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